Valerie Morisset - Oct 31, 2022 Form 4 Insider Report for Eliem Therapeutics, Inc. (ELYM)

Role
EVP, R&D and CSO
Signature
/s/ Alan Hambelton, Attorney-in-Fact
Stock symbol
ELYM
Transactions as of
Oct 31, 2022
Transactions value $
$0
Form type
4
Date filed
11/2/2022, 07:11 PM
Previous filing
Jan 31, 2022
Next filing
Mar 14, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ELYM Common Stock 150K Oct 31, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELYM Stock Option (Right to Buy) Award $0 +170K $0.00 170K Oct 31, 2022 Common Stock 170K $3.27 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of October 31, 2022 (the "2022 Vesting Commencement Date") for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2022 Vesting Commencement Date.